Vascular Biogenics Ltd (VBLT): VBL Therapeutics to Report Second Quarte...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Vascular Biogenics Ltd (VBLT)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	145
Posts	27550
Boards Moderated	3
Alias Born	02/07/2004

Re: None

Thursday, 08/05/2021 8:16:39 AM

Thursday, August 05, 2021 8:16:39 AM

VBL Therapeutics to Report Second Quarter Financial Results on August 16
Vascular Biogenics Ltd.

https://finance.yahoo.com/news/vbl-therapeutics-report-second-quarter-110000033.html

Thu, August 5, 2021, 2:00 PM

TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update.

Conference Call:

Monday, August 16, 2021 at 8:30am EDT

Conference ID: 13721456

US: 1 877 407 9208

Israel Local: 1 809 406 247

International: 1 201 493 6784

Webcast: https://edge.media-server.com/mmc/p/9trg9snq

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a publicly traded (Nasdaq: VBLT), clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune- or inflammatory-related indications. The VBL Therapeutics pipeline has been developed utilizing the company’s three proprietary platform technologies: a gene therapy-based platform technology targeting newly formed blood vessels, an antibody-based technology platform targeting MOSPD2 (motile sperm domain containing 2) and a lecinoxoids platform comprised of a family of small-molecules. The company’s lead oncology candidate, VB-111 (ofranergene obadenovec; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in a phase 3 potential registration trial for platinum-resistant ovarian cancer.

CONTACT:
Burns McClellan for VBL Therapeutics
Lee Roth & Eric Ando (Investors)
LRoth@burnsmc.com & EAndo@burnsmc.com
+1-212-213-0006

Robert Flamm & Harrison Wong (Media)
RFlamm@burnsmc.com & HWong@burnsmc.com
+1-212-213-0006

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent VBLT News

Form 8-K - Current report • Edgar (US Regulatory) • 04/12/2024 12:44:49 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/11/2024 09:00:40 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 09:20:13 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2024 04:15:14 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:30:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2024 01:00:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:15:22 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/16/2024 02:00:13 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/05/2024 10:00:08 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:05:36 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:05:45 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:05:20 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:04:43 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:04:24 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 04:02:17 PM
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/11/2024 10:22:04 PM
Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 01/08/2024 09:21:10 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:00:38 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:00:22 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:00:21 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 10:00:09 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 01:15:18 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/29/2023 10:15:27 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/29/2023 10:00:40 PM

More VBLT News

InvestorsHub NewsWire

Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM

ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM

Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM

Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM

Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM

Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow